Sunovion
Sunovion
Sunovion (pronounced: suh-NOH-vee-on) is a pharmaceutical company that specializes in the research, development, and commercialization of therapeutic products. The company is a subsidiary of Sumitomo Dainippon Pharma, a leading global pharmaceutical company based in Japan.
Etymology
The name "Sunovion" is derived from the Latin words "sun" and "novus", which mean "new" and "innovation" respectively. The company's name reflects its commitment to creating innovative solutions for patients with serious medical conditions.
History
Sunovion was established in 1984 as Sepracor Inc. In 2009, it was acquired by Sumitomo Dainippon Pharma and renamed Sunovion Pharmaceuticals Inc. The company's headquarters are located in Marlborough, Massachusetts, USA.
Products
Sunovion's product portfolio includes treatments for conditions such as schizophrenia, bipolar disorder, depression, chronic obstructive pulmonary disease (COPD), asthma, and epilepsy. Some of the company's well-known products include Latuda® (for schizophrenia and bipolar depression), Aptiom® (for epilepsy), and Brovana® (for COPD).
Research and Development
Sunovion is committed to advancing the science of medicine to improve the lives of patients and their families. The company's research and development efforts are focused on areas of high unmet medical need, including neuroscience, respiratory, and oncology.
Related Terms
- Pharmaceutical industry
- Therapeutics
- Sumitomo Dainippon Pharma
- Schizophrenia
- Bipolar disorder
- Depression
- Chronic obstructive pulmonary disease (COPD)
- Asthma
- Epilepsy
- Neuroscience
- Respiratory
- Oncology
External links
- Medical encyclopedia article on Sunovion
- Wikipedia's article - Sunovion
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski